ATE96679T1 - Makromolekulare platin-antitumorverbindungen. - Google Patents

Makromolekulare platin-antitumorverbindungen.

Info

Publication number
ATE96679T1
ATE96679T1 AT88301410T AT88301410T ATE96679T1 AT E96679 T1 ATE96679 T1 AT E96679T1 AT 88301410 T AT88301410 T AT 88301410T AT 88301410 T AT88301410 T AT 88301410T AT E96679 T1 ATE96679 T1 AT E96679T1
Authority
AT
Austria
Prior art keywords
antitumors
compounds
platinum
macromolecular
macromolecular platinum
Prior art date
Application number
AT88301410T
Other languages
English (en)
Inventor
Anthony J Serino
Geoffrey W Henson
David A Schwartz
Donald H Picker
Original Assignee
Johnson Matthey Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey Inc filed Critical Johnson Matthey Inc
Application granted granted Critical
Publication of ATE96679T1 publication Critical patent/ATE96679T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Insulating Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT88301410T 1987-02-25 1988-02-19 Makromolekulare platin-antitumorverbindungen. ATE96679T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/018,715 US4793986A (en) 1987-02-25 1987-02-25 Macromolecular platinum antitumor compounds
EP88301410A EP0280474B1 (de) 1987-02-25 1988-02-19 Makromolekulare Platin-Antitumorverbindungen

Publications (1)

Publication Number Publication Date
ATE96679T1 true ATE96679T1 (de) 1993-11-15

Family

ID=21789419

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88301410T ATE96679T1 (de) 1987-02-25 1988-02-19 Makromolekulare platin-antitumorverbindungen.

Country Status (12)

Country Link
US (1) US4793986A (de)
EP (1) EP0280474B1 (de)
JP (1) JPS63284134A (de)
AT (1) ATE96679T1 (de)
AU (1) AU596774B2 (de)
CA (1) CA1305665C (de)
DE (1) DE3885317T2 (de)
DK (1) DK96588A (de)
IE (1) IE63003B1 (de)
NO (1) NO175964C (de)
NZ (1) NZ223549A (de)
ZA (1) ZA881077B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952676A (en) * 1984-06-27 1990-08-28 Johnson Matthey Plc Monoclonal antibody-platinum co-ordination compound complex
US4956454A (en) * 1984-06-27 1990-09-11 Johnson Matthey Plc Monoclonal antibody - platinum co-ordination compound complex
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US4931553A (en) * 1988-05-11 1990-06-05 Gill Devinder S Platinum-polymer complexes and their use as antitumor agents
SU1685944A1 (ru) * 1988-06-06 1991-10-23 Институт Физической Химии Им.Л.В.Писаржевского Способ получени комплексного соединени платины (II) с высокомолекул рной н-ДНК из селезенки крупного рогатого скота марки А, обладающего противоопухолевой активностью
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US5639624A (en) * 1989-03-14 1997-06-17 Board Of Regents Of The University Of Nebraska Monoclonal antibodies specific for metallic cations and method therefor
AU648022B2 (en) * 1989-03-14 1994-04-14 Bionebraska, Inc. Monoclonal antibodies for metallic cations on small molecules
US5972656A (en) * 1989-03-14 1999-10-26 Bionebraska, Inc. Mercury binding polypeptides and nucleotides coding therefore
ATE127476T1 (de) * 1990-04-06 1995-09-15 Univ Tulane Lhrh-analoge.
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
ES2170105T3 (es) * 1993-10-04 2002-08-01 Pasteur Institut Compuestos que modifican la transmision serotoninergica; aplicaciones diagnosticas y terapeuticas.
DE69520528T2 (de) * 1994-06-14 2001-09-27 Raffinerie Tirlemontoise, S.A. Verwendung einer Zusammensetzung enthaltend Inulin oder Oligofructose als Antikrebsmittel
WO1996000079A1 (en) * 1994-06-27 1996-01-04 The General Hospital Corporation Graft co-polymer adducts of platinum (ii) compounds
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US6111079A (en) * 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
JP2002508758A (ja) * 1997-06-12 2002-03-19 エムエル・ラボラトリーズ・パブリック・リミテッド・カンパニー 生物的に活性な材料
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
CA2396702C (en) * 2000-01-04 2010-03-23 Access Pharmaceuticals, Inc. N,o-amidomalonate platinum complexes
AU2001247697B2 (en) 2000-03-22 2006-06-22 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US20030082102A1 (en) * 2001-06-25 2003-05-01 Court Wayne S. Radioactive platinum complexes for cancer treatment
WO2003059988A2 (en) * 2002-01-14 2003-07-24 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
CA2492803C (en) 2002-07-19 2013-11-05 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
AU2004270251B2 (en) 2003-09-05 2011-03-31 The General Hospital Corporation Polyacetal drug conjugates as release system
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
EP1745802A1 (de) * 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Verfahren zur Konjugierung therapeutischer Verbindungen an zellgezielten Gruppen über Metallkomplexen
JP5256026B2 (ja) * 2006-04-27 2013-08-07 株式会社ワンセル ヌクレオチド−遷移金属錯体触媒
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US20080300389A1 (en) * 2007-06-04 2008-12-04 Yang David J Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
AR074584A1 (es) 2008-12-10 2011-01-26 Mersana Therapeutics Inc Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
NL2020120B1 (en) * 2017-12-19 2019-06-26 Linxis B V Methods for preparing cell targeting conjugates and conjugates obtainable by said methods
NL2020121B1 (en) * 2017-12-19 2019-06-26 Linxis B V Platinum-based functional moieties for preparing cell targeting conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4385046A (en) * 1980-12-15 1983-05-24 Minnesota Mining And Manufacturing Company Diagnostic radio-labeled polysaccharide derivatives
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
IL66338A (en) * 1982-07-15 1986-03-31 Yeda Res & Dev Anti-cancer drugs comprising platinum complexed antitumor immunoglobulins
US4584392A (en) * 1982-11-10 1986-04-22 Inco Alloys International, Inc. Platinum and palladium complexes
IL67789A (en) * 1983-01-31 1986-09-30 Yissum Res Dev Co Amino-substituted malonato platinum(ii)complexes and method for their preparation
US4673754A (en) * 1983-10-14 1987-06-16 Inco Alloys International, Inc. Platinum and palladium complexes
DE3582961D1 (de) * 1984-06-27 1991-07-04 Johnson Matthey Plc Platinkoordinationsverbindungen.
IL73972A0 (en) * 1984-12-31 1985-03-31 Yeda Res & Dev Agents based on platinum compounds

Also Published As

Publication number Publication date
NZ223549A (en) 1989-10-27
DE3885317T2 (de) 1994-03-03
US4793986A (en) 1988-12-27
NO175964B (no) 1994-10-03
IE880498L (en) 1988-08-25
EP0280474A2 (de) 1988-08-31
DK96588A (da) 1988-08-26
NO175964C (no) 1995-01-11
EP0280474B1 (de) 1993-11-03
CA1305665C (en) 1992-07-28
AU1213588A (en) 1988-09-01
AU596774B2 (en) 1990-05-10
JPS63284134A (ja) 1988-11-21
ZA881077B (en) 1988-08-11
NO880705L (no) 1988-08-26
DK96588D0 (da) 1988-02-24
IE63003B1 (en) 1995-03-08
EP0280474A3 (en) 1990-01-31
NO880705D0 (no) 1988-02-17
DE3885317D1 (de) 1993-12-09

Similar Documents

Publication Publication Date Title
DE3885317D1 (de) Makromolekulare Platin-Antitumorverbindungen.
NO901986L (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
SG47517A1 (en) (1-92-oxo-acetyl)-piperidine-2-carboxylic acid derivatives as multi-drug-resistant cancer cell sensitizers
ATE294595T1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
BR9705727A (pt) Heterocicilos com anel de cinco membros como inibidores da adesão de leucócitos e como antigonistas de vla-4.
DK15589A (da) Kemiske forbindelser
ES8506657A1 (es) Procedimiento para la preparacion de 3-(1-sustituido-4-piperidil)-1, 2-bencisoxazoles
MA18942A1 (fr) Nouvelles benzophenone hydrazones,leur procede de preparation et leur application comme pesticides
GR1000118B (el) Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
FR2326192A1 (fr) Nouvelles pyrimidones, leur procede de preparation et leur application therapeutique
PH18031A (en) Immunoglobulin conjugates,process for preparing them and pharmaceutical composition containing the same
FI810559L (fi) Nya 3,4,5-trihydroxipiperidinderivat foerfaranden foer deras framstaellning och deras anvaendning som laekemedel samt i djurnaering
ES2079068T3 (es) 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas.
BG45552A3 (bg) Метод за получаване на 2-фенил-хексахидро-1,2,4- триазин-3,5-диони
ES483661A1 (es) Procedimiento para la obtencion de derivados de 1,4-dihidro-piridina sila-sustituidos
SE8700555D0 (sv) Purine derivatives, their production and medicaments containing them
DK398483A (da) Substituerede tert.butanol-derivater, fremgangsmaader til fremstilling deraf samt antimykotiske midler indeholdende disse forbindelser
JPS5566547A (en) Alkene derivative*its manufacture and medicine containing it and having sexial excitement control activity
ATE3036T1 (de) 2-substituierte-4-alkyl bzw trihaloalkyl-5oxazolcarbons[urederivate, deren verwendung als antidote fuer kulturpflanzen und sie enthaltende zusammensetzungen.
DE3165050D1 (en) Salt of furosemide or piretanide as acid component and penbutolol as base component and pharmaceutical composition containing both of the said components
NO842345L (no) Heksahydropyrrolo(2,1-a)isoquinolin-derivater.
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
SU568574A1 (ru) Прижимной механизм вертикального двухленточного конвейера
BG45702A3 (bg) Метод за получаване на смеси от серосъдържащи триазинови съединения
ES2061602T3 (es) Polimeros acrilicos imidizados y procedimiento para su preparacion.